181 related articles for article (PubMed ID: 35062321)
41. A dynamic COVID-19 immune signature includes associations with poor prognosis.
Laing AG; Lorenc A; Del Molino Del Barrio I; Das A; Fish M; Monin L; Muñoz-Ruiz M; McKenzie DR; Hayday TS; Francos-Quijorna I; Kamdar S; Joseph M; Davies D; Davis R; Jennings A; Zlatareva I; Vantourout P; Wu Y; Sofra V; Cano F; Greco M; Theodoridis E; Freedman JD; Gee S; Chan JNE; Ryan S; Bugallo-Blanco E; Peterson P; Kisand K; Haljasmägi L; Chadli L; Moingeon P; Martinez L; Merrick B; Bisnauthsing K; Brooks K; Ibrahim MAA; Mason J; Lopez Gomez F; Babalola K; Abdul-Jawad S; Cason J; Mant C; Seow J; Graham C; Doores KJ; Di Rosa F; Edgeworth J; Shankar-Hari M; Hayday AC
Nat Med; 2020 Oct; 26(10):1623-1635. PubMed ID: 32807934
[TBL] [Abstract][Full Text] [Related]
42. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
43. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study.
Chang YJ; Wu DP; Lai YR; Liu QF; Sun YQ; Hu J; Hu Y; Zhou JF; Li J; Wang SQ; Li W; Du X; Lin DJ; Ren HY; Chen FP; Li YH; Zhang X; Huang H; Song YP; Jiang M; Hu JD; Liang YM; Wang JB; Xiao Y; Huang XJ
J Clin Oncol; 2020 Oct; 38(29):3367-3376. PubMed ID: 32650683
[TBL] [Abstract][Full Text] [Related]
44. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.
van Roessel I; Prockop S; Klein E; Boulad F; Scaradavou A; Spitzer B; Kung A; Curran K; O'Reilly RJ; Kernan NA; Cancio M; Boelens JJ
Cytotherapy; 2020 Sep; 22(9):503-510. PubMed ID: 32622752
[TBL] [Abstract][Full Text] [Related]
45. Characterization of a Unique γδ T-Cell Subset as a Specific Marker of Cytomegalovirus Infection Severity.
Kaminski H; Ménard C; El Hayani B; Adjibabi AN; Marsères G; Courant M; Zouine A; Pitard V; Garrigue I; Burrel S; Moreau JF; Couzi L; Visentin J; Merville P; Déchanet-Merville J
J Infect Dis; 2021 Feb; 223(4):655-666. PubMed ID: 32622351
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology of
Dunbar A; Schauwvlieghe A; Algoe S; van Hellemond JJ; Reynders M; Vandecasteele S; Boelens J; Depuydt P; Rijnders B
Front Cell Infect Microbiol; 2020; 10():224. PubMed ID: 32500040
[No Abstract] [Full Text] [Related]
47. γ9δ2T cell diversity and the receptor interface with tumor cells.
Vyborova A; Beringer DX; Fasci D; Karaiskaki F; van Diest E; Kramer L; de Haas A; Sanders J; Janssen A; Straetemans T; Olive D; Leusen J; Boutin L; Nedellec S; Schwartz SL; Wester MJ; Lidke KA; Scotet E; Lidke DS; Heck AJ; Sebestyen Z; Kuball J
J Clin Invest; 2020 Sep; 130(9):4637-4651. PubMed ID: 32484803
[TBL] [Abstract][Full Text] [Related]
48. A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance.
Langenhorst JB; Boss J; van Kesteren C; Lalmohamed A; Kuball J; Egberts ACG; Boelens JJ; Huitema ADR; van Maarseveen EM
Br J Clin Pharmacol; 2020 Aug; 86(8):1499-1509. PubMed ID: 32067250
[TBL] [Abstract][Full Text] [Related]
49. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.
Johanna I; Hernández-López P; Heijhuurs S; Bongiovanni L; de Bruin A; Beringer D; van Dooremalen S; Shultz LD; Ishikawa F; Sebestyen Z; Straetemans T; Kuball J
J Leukoc Biol; 2020 Jun; 107(6):1069-1079. PubMed ID: 32022317
[TBL] [Abstract][Full Text] [Related]
50. γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.
Janssen A; Villacorta Hidalgo J; Beringer DX; van Dooremalen S; Fernando F; van Diest E; Terrizi AR; Bronsert P; Kock S; Schmitt-Gräff A; Werner M; Heise K; Follo M; Straetemans T; Sebestyen Z; Chudakov DM; Kasatskaya SA; Frenkel FE; Ravens S; Spierings E; Prinz I; Küppers R; Malkovsky M; Fisch P; Kuball J
Cancer Immunol Res; 2020 Apr; 8(4):530-543. PubMed ID: 32019779
[TBL] [Abstract][Full Text] [Related]
51. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
52. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.
Rigau M; Ostrouska S; Fulford TS; Johnson DN; Woods K; Ruan Z; McWilliam HEG; Hudson C; Tutuka C; Wheatley AK; Kent SJ; Villadangos JA; Pal B; Kurts C; Simmonds J; Pelzing M; Nash AD; Hammet A; Verhagen AM; Vairo G; Maraskovsky E; Panousis C; Gherardin NA; Cebon J; Godfrey DI; Behren A; Uldrich AP
Science; 2020 Feb; 367(6478):. PubMed ID: 31919129
[TBL] [Abstract][Full Text] [Related]
53. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.
Arruda LCM; Gaballa A; Uhlin M
Blood Adv; 2019 Nov; 3(21):3436-3448. PubMed ID: 31714966
[TBL] [Abstract][Full Text] [Related]
54. Butyrophilin-like 3 Directly Binds a Human Vγ4
Willcox CR; Vantourout P; Salim M; Zlatareva I; Melandri D; Zanardo L; George R; Kjaer S; Jeeves M; Mohammed F; Hayday AC; Willcox BE
Immunity; 2019 Nov; 51(5):813-825.e4. PubMed ID: 31628053
[TBL] [Abstract][Full Text] [Related]
55. Identification of a tumor-specific allo-HLA-restricted γδTCR.
Kierkels GJJ; Scheper W; Meringa AD; Johanna I; Beringer DX; Janssen A; Schiffler M; Aarts-Riemens T; Kramer L; Straetemans T; Heijhuurs S; Leusen JHW; San José E; Fuchs K; Griffioen M; Falkenburg JH; Bongiovanni L; de Bruin A; Vargas-Diaz D; Altelaar M; Heck AJR; Shultz LD; Ishikawa F; Nishimura MI; Sebestyén Z; Kuball J
Blood Adv; 2019 Oct; 3(19):2870-2882. PubMed ID: 31585951
[TBL] [Abstract][Full Text] [Related]
56. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies.
Laberko A; Sultanova E; Gutovskaya E; Shipitsina I; Shelikhova L; Kurnikova E; Muzalevskii Y; Kazachenok A; Pershin D; Voronin K; Shcherbina A; Maschan M; Maschan A; Balashov D
Blood; 2019 Nov; 134(20):1755-1763. PubMed ID: 31558465
[TBL] [Abstract][Full Text] [Related]
57. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
Front Immunol; 2019; 10():1997. PubMed ID: 31507601
[TBL] [Abstract][Full Text] [Related]
58. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.
Sebestyen Z; Prinz I; Déchanet-Merville J; Silva-Santos B; Kuball J
Nat Rev Drug Discov; 2020 Mar; 19(3):169-184. PubMed ID: 31492944
[TBL] [Abstract][Full Text] [Related]
59. γδ T-cell responses during HIV infection and antiretroviral therapy.
Juno JA; Eriksson EM
Clin Transl Immunology; 2019; 8(7):e01069. PubMed ID: 31321033
[TBL] [Abstract][Full Text] [Related]
60. Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells.
Di Lorenzo B; Simões AE; Caiado F; Tieppo P; Correia DV; Carvalho T; da Silva MG; Déchanet-Merville J; Schumacher TN; Prinz I; Norell H; Ravens S; Vermijlen D; Silva-Santos B
Cancer Immunol Res; 2019 Apr; 7(4):552-558. PubMed ID: 30894378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
